PubRank

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Clinical Trial ID NCT01294202

PubWeight™ 14.51‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01294202

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011 3.55
2 Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2011 2.21
3 Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs 2014 1.21
4 Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther 2014 1.18
5 Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol 2014 1.00
6 The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther 2012 0.92
7 A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Mol Cancer 2013 0.90
8 Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol Oncol Clin North Am 2013 0.84
9 Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions. Drugs 2015 0.83
10 Heat shock protein 90 inhibition: rationale and clinical potential. Ther Adv Med Oncol 2012 0.82
11 Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. Eur J Cancer 2016 0.78
12 Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor. Expert Opin Investig Drugs 2015 0.75
Next 100